Is a Longer Schedule of Decitabine More Effective Than a 5-Day Schedule in Older...
For older patients with treatment-naïve acute myeloid leukemia (AML), research has suggested that a 10-day treatment schedule of the hypomethylating agent decitabine is associated...
Ibrutinib Plus Obinutuzumab Superior to Standard Chemoimmunotherapy in Treatment-Naïve Chronic Lymphocytic Leukemia
Treatment with the regimen of ibrutinib plus obinutuzumab improved outcomes for patients with previously untreated chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL),...
Restrictive Transfusion Therapy Safe for Cardiac Surgery Patients
Setting higher hemoglobin (Hb) thresholds for red-cell transfusion therapy in patients undergoing cardiac surgery with a moderate to high risk of death was noninferior...
Medicare Part D Beneficiaries With Myeloma Receive Novel Therapies More Frequently, Have Better Survival...
People with myeloma who have prescription drug coverage under Medicare are less likely to use older cytotoxic chemotherapy and more likely to receive newly...
Emicizumab Prophylaxis Reduces Bleeding Events in Hemophilia A Without Inhibitors
Treatment with emicizumab was associated with lower bleeding rates, compared with no prophylaxis, in patients with hemophilia A without inhibitors, according to findings from...
No Added Benefit When Hydroxyurea Is Combined With Aspirin in Middle-Aged Patients With Essential...
Cytoreductive treatment with hydroxyurea has been shown to reduce the risk of thrombosis in patients with essential thrombocythemia (ET) and high-risk features, which include...
Researchers Identify Genetic Prognostic Predictors in Myeloproliferative Neoplasms
A team of European and American researchers have identified and characterized associations between specific genetic mutations and prognosis in patients with myeloproliferative neoplasms (MPNs),...
BCMA-Targeting CAR T-Cell Therapy Shows High Response Rate in Pretreated Myeloma
Multiple myeloma (MM) is a potential target for chimeric antigen receptor (CAR) T-cell therapies, according to final results from a first-in-human trial of B-cell...
A New Source of “Superwarfarin” Poisoning: Increased Bleeding Risk After Synthetic Cannabinoid Use
In the New England Journal of Medicine (NEJM), authors reported a case series of patients with synthetic cannabinoid–associated coagulopathy, identifying contamination with brodifacoum, or...
Higher Childhood Leukemia Risk in Offspring Raises Questions About Hormonal Contraceptive Safety
Children born to women who were using hormonal contraception within three months of pregnancy and during pregnancy have a higher risk of developing myeloid...
Current Issue
January 2019 Annual Meeting Edition
This issue features highlights from the 2018 ASH Annual Meeting, including big data initiatives to improve prognosis in myelodysplastic syndromes, and more.
